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Abstract
Background: Cyclooxygenase-2 overexpression is associated with poor outcome and resistance to platinum-based
chemotherapy in ovarian cancer. We evaluated the antitumor activity and safety of the combination carboplatin
plus the COX-2 inhibitor celecoxib in recurrent heavily-treated OC patients.
Methods: Patients were administered oral celecoxib (400 mg/day) in combination with intravenous carboplatin
(AUC5, q28). A Simon’s two-stage design was employed.
Results: 45 patients were enrolled: 23 (51.1%) presented platinum-resistance, and 27 (60%) had received at least 3
prior regimens for recurrence. The response rate was 28.9% with 3 complete and 10 partial responses (median
duration of response = 6 months). Only one (0.4%) G4 non-febrile neutropenia was observed; G3 neutropenia,
anemia, or thrombocytopenia, were observed in 2.5%, 1.7%, and 1.7% of the cycles, respectively. G3-4 vomiting was
reported in only 1.7%, and 0.4% of the cycles were associated with G3 dyspepsia or diarrhea or constipation. Only
one patient experienced G3 hypertension associated to G2 hypersensitivity reaction. No differences in baseline
versus post-treatment Quality of Life scores were observed. Median progression free survival and overall survival
were 5 and 13 months, respectively.
Conclusions: Celecoxib combined with carboplatin showed promising activity and it is well tolerated in heavily-
treated recurrent ovarian cancer patients.
Trial registration number: NCT01124435 (ClinicalTrials.gov Identifier) and 935/03 (study ID numbers).
Background
Most ovarian cancer (OC) patients experience recurrence
of disease within 2 years from initial treatment, and typi-
cally are re-treated with platinum-based combinations, if
considered platinum-sensitive (interval to recurrence/pro-
gression longer than 6 months) [1,2] or with non-platinum
agents, such as liposomal doxorubicin, gemcitabine, topo-
tecan, if considered platinum-resistant (interval to recur-
rence/progression less than 6 months from the
completion of primary treatment) [3,4]. However, going
on to receive multiple lines of chemotherapy, platinum re-
treatment is very often attempted, also after the adminis-
tration of several non-platinum drugs, and shows response
rates ranging from 6 to 23% [5-7]. Given the palliative
intent of any medical treatment of recurrent OC [8,9], the
integration of non-cytotoxic drugs to standard chemother-
apy has been proposed as a strategy to both increase
response rates and/or decrease dose intensity and treat-
ment related toxicity. In particular, novel strategies aimed
at increasing platinum sensitivity should theoretically take
advantage of targeting molecules not only involved in key
steps of cancer biology such as proliferation/apoptosis bal-
ance, angiogenesis or immunosuppression, but also che-
moresistance. In this context, cyclooxygenase-2 (COX-2),
the key enzyme in prostaglandins (PGs) synthesis, seems
to be a very suitable target, since it is involved in each of
the above mentioned processes, it is overexpressed in
tumors exhibiting pathological and clinical features of
aggressiveness, and it is also associated with platinum-
resistance and unfavorable prognosis in OC as well as in
other human malignancies [10-14].
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in vitro and in vivo to exert a potent tumor growth inhi-
bition not only in COX-2 positive tumors, but also
indirectly in COX-2 negative tumors, through the
growth inhibition of COX-2 expressing endothelial cells,
and the positive modulation of immune functions
[15,16]. Selective COX-2 inhibitors have been shown to
be active as tumor chemopreventive agents in preclinical
models as well as in humans [15,17,18], and to enhance
the cytotoxicity exerted in vitro by different chemothera-
peutics, including platinating agents [19,20].
The safety of celecoxib, which, amongst COX-2 inhi-
bitors, exhibits the greatest potency for growth inhibi-
tion [21], has been extensively studied in patients with
arthritis: at doses of 400 mg/day, celecoxib presents a
toxicity profile similar to traditional non-steroidal
inflammatory drugs, with the advantages of a reduced
incidence of gastric ulcers and symptomatic gastrointest-
inal adverse events [22]. Although long-term use of
COX-2 inhibitors has come recently under scrutiny due
to the documentation of increased risk of serious cardio-
vascular events in patients treated with celecoxib at 400-
800 mg/day, the hazard ratio for death from cardiovas-
cular causes, has been reported to be 2.3 in the low
dose group [23]. Even though it is unlikely that cardio-
vascular toxicity could affect the clinical outcome of
poor prognosis recurrent OC patients, these data have
been considered in the selection of the celecoxib’sd o s e
(400 mg/day) and in the eligibility criteria of the study.
Based on these evidences, we conducted a phase II
clinical trial aimed at evaluating the antitumor activity
and potential adverse effects of the combination cele-
coxib plus carboplatin in patients with recurrent, heavily
pre-treated OC who had exhausted treatment options.
The potential changes induced by the experimental
combination on angiogenesis-related serum markers and
quality of life measures were also evaluated.
Methods
Study population
This study was approved by the Institutional Ethical
Committee of the Catholic University of Rome. The trial
registration numbers for this phase II study are
NCT01124435 (ClinicalTrials.gov Identifier) and 935/03
(study ID numbers). Eligible patients were required to
have recurrent epithelial ovarian, fallopian tube, or peri-
toneal serous carcinomas with measurable disease as
assessed by Response Evaluation Criteria in Solid
Tumors (RECIST) criteria [24]. Patients were required
to have received a platinum-containing regimen as pri-
mary treatment, at least one line of chemotherapy for
recurrent disease. An interval time from the last plati-
num-based chemotherapy > 6 months, ≥18 years of age,
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0 to 2, adequate bone marrow (absolute
granulocyte count ≥1,500/μl, hemoglobin >8.5 g/dl, and
platelets count ≥100,000/≥30 ml/min), and hepatic
(bilirubin ≤1.5 times upper limit of normal [ULN] and
AST or ALT ≤3t i m e sU L N )f u n c t i o nw e r ea l s o
required. Patients had to provide a written informed
consent to the study protocol. Major exclusion criteria
included: hypersensitivity to celecoxib, aspirin, other
nonsteroidal anti-inflammatory drugs (NSAIDs), or sul-
fonamides; significant comorbidities (including any
active coronary artery disease requiring management,
symptomatic congestive heart failure, bleeding diathesis,
uncontrolled severe hypertension, active gastrointestinal
ulcer within 12 months, chronic inflammatory bowel
diseases, deep venous or arterial thrombosis within 12
months, history of pulmonary embolism); concomitant
use of possible interactive drugs (including chronic use
of other NSAIDs); surgery, chemotherapy or radiother-
apy within 1 month; actual or potential childbearing;
breast-feeding; prior cancer treatment with a COX-2
inhibitor; any psychological, sociological or geographical
condition potentially hampering compliance with the
study protocol and follow-up schedule.
All eligible patients were included in the analysis of
response, toxicity, quality of life (QoL), progression-free
survival (PFS) and overall survival (OS) measures.
Primary and secondary platinum resistance have been
defined as progression of disease within 6 months of
completion of first line or salvage, respectively, plati-
num-based therapy. Platinum refractoriness is progres-
sion while on first line platinum-based therapy.
Study design
This phase II prospective study was conducted at the
Gynecologic Oncology Units of the Catholic University
of Rome and Campobasso, Italy. The study was non-
sponsored, investigators initiated. The primary objective
was to determine the tumor response rate by RECIST
criteria [24]. Secondary objectives included duration of
response, progression-free survival (PFS), overall survival
(OS), toxicity assessment, and QoL measures.
Patients were required to take celecoxib (200 mg
tablets by mouth twice daily, day 1 to 28), in combina-
tion with intravenous carboplatin (area under the curve
(AUC) 5 over 30 to 60 minutes, every 28 days). Patients
who developed carboplatin hypersensitivity reaction
(HSR) were allowed to follow a desensitization protocol,
or alternatively to switch to cisplatin [25].
Erythropoietic stimulating agent and myeloid growth
factors were not permitted for cycle 1 of study treat-
ment, and their use was chosen by the treating physi-
cian, according to hospital policy.
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Before starting treatment, patients were evaluated by
medical history, physical examination, cell blood count
(CBC), chemistry panel, Ca125, and either computed
tomography or magnetic resonance imaging scan. Toxi-
cities were reported using the National Cancer Institute
Common Terminology Criteria for Adverse Events ver-
sion 3 [26]. Patients underwent weekly CBC and
biweekly chemical panel during treatment. All laboratory
tests were re-checked on day 1 of each cycle. Any
patient receiving at least two cycles was assessable for
tumor response, every three cycles, by RECIST criteria
[24]. Clinical benefit was defined as a complete/partial
response or a disease stabilization for at least 3 months.
Toxicity was assessed at every cycle.
In addition, the criteria modified by Rustin [27] were
used to define serological response: complete response
was defined as the normalization of Ca125 serum levels
to ≤35 U/ml confirmed by a second Ca125 measure-
ment after 28 days, partial response was defined as a
≥50% decrease in Ca125 level after initiation of treat-
ment confirmed 28 days apart, progression of disease
was defined as a ≥50% increase in Ca125 level con-
firmed after 28 days, while stable disease was considered
to be any response other than complete or partial
response, or progression of disease.
Within 1 week before enrollment and every 3 cycles,
QoL was assessed using the European Organization for
Research and Treatment of Cancer Quality of Life
Questionnaire C30 [28].
Dose modifications and delay
To receive chemotherapy, patients needed to have an
absolute granulocyte count of ≥1,500/μl, hemoglobin
>8.5 g/dl, platelets count of ≥100,000/μl, and resolution
of toxicities to ≤g r a d e1 .N od o s er e d u c t i o nw a s
planned. Patients were removed from study if toxicities
were not recovered by day 42 from the last cycle
administration.
Discontinuation of treatment
Treatment was discontinued when any of the following
events occurred: radiographic or clinical evidence of
cancer progression; deterioration of health or intolerable
toxicity; patient refusal. Once patients stopped treat-
ment, post-study treatment was dictated by the treating
physician.
Assessment of circulating levels of angiogenesis
regulatory molecules
Plasma samples were collected in tubes containing
heparin and serum was obtained using a serum separator
tube (1500 RPM for 10 minutes at 4°C). All samples were
aliquoted and stored at -80°C until assay. Serum levels of
vascular endothelial growth factor (VEGF) and endostatin
were measured by a solid phase chemiluminescent ELISA
assay (R&D Systems, Abingdon, United Kingdom),
according to the manufacturer’s protocol [16].
Statistical design and analysis
The primary endpoint was to determine the overall
response (OR) rate. Secondary endpoints included the
assessment of duration of response, PFS, OS, toxicity
e v e n t sa n dQ o Ls c o r e s .T h eO Rr a t e ,i . e .t h ec o m b i n e d
rate of complete and partial responses, was reported as
the proportion of the events among all patients, and was
calculated via the intent-to-treat population. A Simon’s
two-stage accrual design was employed with an early
stopping rule in the event that the treatment demon-
strated insufficient activity. During the first stage of
accrual, 13 patients were to be entered and evaluated. If
at least 4 responses were observed among the first 13
patients, a second phase of accrual was to be initiated
which would increase the accrual to 43 patients. The
treatment would be considered active if at least 13
responses were observed among 43 patients. If the true
probability of responding was only 20% (H0<13
responses), the study design provided a 95% chance of
correctly classifying the treatment as inactive (alfa =
0.05). Conversely, if the true response rate was 40%
(Ha≥13 responses), then the probability of correctly clas-
sifying the treatment as effective was 80% (beta = 0.8).
Duration of response was measured from the time
that measurement criteria for response were met until
the first date that progressive disease was documented.
PFS and OS were measured from the date of start of
study treatment to the date of evidence of progression
or last seen, and the date of death from any cause or
last seen, respectively. Toxicity events were summarized
descriptively by frequency distribution.
Frequency counts and percentages were used to
describe categorical variables, and median and range
were used for continuous variables. Significance of dif-
ferences between response rate in the different groups
was calculated by the Fisher’s exact test. Changes in
QoL measures and VEGF and endostatin levels from
baseline scores were compared using the Wilcoxon
signed rank sum test. Survival probabilities were esti-
mated according to the method of Kaplan and Meier
[29]. Statistical analysis was carried out using SOLO
(BMDP Statistical Software, Los Angeles, CA)
Results
Enrollment and Demographics
Between October 2003 and September 2007, 45 patients
were enrolled.
Demographics and baseline characteristics of the study
population are listed in Table 1. Most of the patients
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entiation (80.6%). All patients were treated with plati-
num-based therapy including (82.2%) or not (17.8%)
taxanes at time of initial diagnosis. Median progression-
free interval from first line chemotherapy was 11
months (range, 2 to 66 months). Thirteen patients
(28.9%) presented primary platinum-resistance, while 10
patients (22.2%) showed secondary platinum-resistance.
The remaining 22 (48.9%) patients presented a “relative
sensitivity” to platinum, since 10 cases achieved only a
partial response to first line chemotherapy while 12
cases experienced disease progression within 6-12
months from the end of first line chemotherapy, accord-
ing to previously defined criteria [3,5].
Twenty-seven patients (60%) had received ≥ 3p r i o r
chemotherapy regimens for recurrent disease. Median
interval from the last platinum-based chemotherapy
(primary or re-challenge) was 22 months (range, 8 to 48
months). At time of study enrollment, median age was
59 years (range, 34 to 74), and 44.4% of patients had an
ECOG performance status of 0.
Response Rates
Table 2 shows the results of treatment efficacy in the
intent-to-treat population (n = 45), as well as in patients
who received at least 2 cycles of the study treatment (n
= 42). Indeed, three patients refuse to continue the
treatment before two cycles were completed (see below).
In the intent-to-treat population, the overall response
rate was 28.9% with 3 complete (6.7%), and 10 partial
(22.2%) responses. Most responses (n = 11, 84.6%) were
documented after 3 cycles of treatment; the median
duration of response was 6 months (range, 3 to 13
months). Thirteen patients (28.9%) experienced stabiliza-
tion of disease (median duration = 5 months, range 3 to
10 months), while 19 patients (42.2%) had progressive
disease. Overall, 26 (57.8%) patients experienced a clini-
cal benefit.
One (25%) response was observed among 4 platinum-
refractory patients, 3 (15.8%) responses among 19 plati-
num-resistant patients and 9 (40.9%) responses among the
22 patients with relative sensitivity to platinum: although
considering the limits of a small series, the response rate
was not associated with platinum sensitivity (17.4% in
resistant versus 40.9% in relatively sensitive cases, p =
0.11). Moreover, the response rate, was not associated
with the interval from the last platinum (data not shown).
No difference was noted in the response rates of
patients who have completed at least two cycles of the
experimental combination: indeed, objective response
rate was 30.9% with a clinical benefit observed in 59.5%
of the patients.
When considering the serological responses, we docu-
mented the return to the normal Ca125 levels, and the
reduction ≥ 50% in Ca125 levels, in 8 (19.0%), and 9
(21.4%) patients, respectively; serological stabilization of
disease was observed in 12 (28.6%) patients, totaling 29
(69.0%) patients not experiencing Ca125 increase during
the study protocol (Table 2).
Toxicities
Table 3 shows the study drugs administration details. In
the whole study population a total of 238 cycles of plati-
num-based chemotherapy was administered, 196 of
which included celecoxib; the median number of plati-
num plus celecoxib cycles per patient was 3 (range 1-
10). Neither dose reductions, nor dose delays were
recorded. Treatment withdrawal was registered for the
Table 1 Clinical/pathological characteristics of the study
population (n = 45)
Characteristics No (%)
Histotype
Serous 33 (76.7)
Endometrioid 3 (7.0)
Clear cell 2 (4.6)
Undifferentiated 3 (7.0)
Other 4 (8.9%)
Grade
G1-2 7 (19.4)
G3 29 (80.6)
n.a. 9
First line Chemotherapy
Platinum-based 8 (17.8)
Platinum/taxane-based 37 (82.2)
Platinum sensitivity
Primary refractoriness 4 (8.9)
Primary resistance 9 (20.0)
Secondary resistance 10 (22.2)
Relative sensitivity 22 (48.9)
No. previous chemotherapy lines for recurrence
treatment
1 6 (13.3)
2 12 (26.7)
3 19 (42.2)
≥4 8 (17.7)
No. previous platinum-based re-challenges
None 25 (55.5)
1 17 (37.8)
2 3 (6.7)
Age, years
Median (range) 59 (34-
74)
ECOG PS
0 20 (44.4)
1 23 (51.1)
2 2 (2.5)
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sal due to G1 vertigo (n = 1), G1 motor neurotoxicity (n
= 1), G3 carboplatin HSR and refusal of the de-sensiti-
zation protocol or re-challenge with cisplatin (n = 1),
G3 diarrhea (n = 1), and G2 diarrhea associated with
G2 rectal bleeding (n = 1): the last three patients experi-
enced early toxicity during the first 5 weeks of treatment
and refused further continuation of the experimental
combination; b) in 4 cases because of toxicity including
G3 hypertension associated to G2 HSR (n = 1), G2 skin
desquamation (n = 1), G2 abdominal pain (n = 1), G3
dyspepsia (n = 1); c) in 28 patients (62.2%) due to pro-
gression of disease; d) in 8 patients after achieving
response to treatment.
Table 4 lists the toxicities observed. Only one case
(0.4% of the cycles) of G4 hematological toxicity was
observed, and no patient experienced febrile neutrope-
nia. Grade 3 anemia, neutropenia, or thrombocytopenia,
were observed in 1.7%, 2.5%, and 1.7% of the cycles,
respectively. Only one patient was prescribed myeloid
growth factor support at some point during therapy (7
cycles, 2.9% of the cycles); erytropoietin was prescribed
in one patient (4 cycles, 1.7% of the cycles).
As far as nonhematological toxicity is concerned, G3-
G4 vomiting was reported in only 1.7% of cycles, while
G3 dyspepsia, or diarrhea, or constipation were observed
in 0.4% of cycles, respectively.
Six patients (13.3%) experienced carboplatin HSR dur-
ing treatment (G2, n = 2; G3, n = 4): three patients had
received prior platinum in the recurrent setting, whereas
the remaining 3 had received platinum as part of the
primary treatment. One patient refused further treat-
ment, while the remaining 5 were switched to cisplatin.
All patients experiencing G3 HSR required intravenous
medication with diphenydramine and corticosteroids
during the reaction.
Quality of life measures
Overall, 32 patients (71.1%) completed the QoL ques-
tionnaire at baseline and at least one time after study
treatment. For all scales/items, there was no statistically
significant difference in baseline scores with respect to
scores evaluated after three cycles of treatment: median
global QoL score was 5 (range 2-7) versus 4.5 (range 1-
7), at baseline and post-treatment, respectively (p value
= 0.24). Moreover, the patterns of change in individual
patients were not associated to clinical response (data
not shown).
Post-study treatments
Twenty-one (47%) patients were submitted to palliative
care, in 16 (35%) oral/intravenous cyclophosphamide or
Table 2 Response rates based on Intent-to-Treat population (n = 45) and in patients who have completed at least two
cycles of the experimental combination (n = 42)
Characteristics Intent-to-Treat patients
No (%)
Patients completing at least two cycles of treatment
No (%)
Patients 45 42
Clinical response
Complete 3 (6.7) 3 (7.1)
Partial 10 (22.2) 10 (23.8)
Stable disease 13 (28.9) 12 (28.6)
Progression 19 (42.2) 17 (40.5)
Duration of response, months
Median (range)
6 (3-13) 6 (3-13)
Duration of stabilization, months
Median (range)
5 (3-10) 5 (3-10)
Serological Response*
Complete 8 (19.0) 8 (20.5)
Partial 9 (21.4) 8 (20.5)
Stabilization 12 (28.6) 11 (28.2)
Progression 13 (31.0) 12 (30.8)
*Patients with 2 pre-treatment samples above the upper limit of normal (35 U/ml) Ca125 levels, and at least 2 additional samples after the start of treatment (n = 42).
Table 3 Study drugs administration details
Total chemotherapy cycles administered 238
Total chemotherapy + celecoxib cycles administered 196
Chemotherapy + celecoxib cycles per patient, median
(range)
3 (1-10)
Reason for treatment withdrawal
Patient’s refusal 5 (11.1)°
Toxicity 4 (8.9)°
Progression of disease 28 (62.2)
Patient’s decision after confirmation of response 8 (17.8)*
°See Table 4 for details
* All patients submitted to ≥ 6 cycles of treatment.
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treated with other cytotoxics such as weekly gemcitabine
or taxanes.
Survival
The median duration of follow-up was 12.0 months
(range 3-46). PFS and OS curves for the study popula-
tion are shown in Figure 1. Median PFS was 5 months
with 39.2% of patients alive without disease progression
after 6 months from the enrollment. Median OS was 13
months with 81.9% of patients alive after 6 months from
the enrollment.
In the group of 26 patients experiencing a clinical
benefit to the study treatment, a median PFS of 8
months and a median OS of 17 months was recorded.
Assessment of circulating levels of angiogenesis
regulatory molecules
Serum levels of VEGF and endostatin were evaluated in
a preliminary series of 11 patients at baseline and after
1 month of carboplatin-celecoxib. Neither VEGF or
endostatin levels resulted significantly changed in paired
pre- and post-treatment samples: median VEGF serum
Table 4 Treatment-related toxicity graded by the Common Toxicity Criteria (version 3.0): overall assessment of
adverse events per cycle (n=238)
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Hematological
Anemia 48 (20.2) 42 (17.6) 4 (1.7) 0
Neutropenia 32 (13.4) 38 (16.0) 6 (2.5) 1 (0.4)
Thrombocytopenia 10 (4.2) 14 (5.9) 4 (1.7) 0
Gastrointestinal
Nausea 26 (10.9) 10 (4.2) 0 0
Vomiting 18 (7.6) 8 (3.4) 3 (1.3) 1 (0.4)*
Dyspepsia 7 (2.9) 0 1 (0.4)° 0
Constipation 8 (3.4) 6 (2.5) 1 (0.4)* 0
Diarrhea 5 (2.1) 7 (2.9) 1 (0.4)° 0
Rectal bleeding 0 1 (0.4)° 0 0
Abdominal pain 1 (0.4) 2 (0.8)° 0 0
AST/ALT elevation 4 (1.7) 0 0 0
Neurological
Hypoacusia 1 (0.4) 1 (0.4) 0 0
Sensitive Neurotoxicity 2 (0.8) 0 0 0
Motor Neurotoxicity 2 (0.8) ° 0 0 0
Vertigo 1 (0.4)° 0 0 0
Fatigue 13 (5.5) 6 (2.5) 2 (0.8) 0
Venous thrombosis 1 (0.4) 0 0 0
Skin (erythema/desquamation) 5 (2.1) 1 (0.4)° 0 0
Hypertension 0 1 (0.4) 1 (0.4) ° 0
Renal failure 0 1 (0.4) 0 0
Carboplatin HSR 1 (0.4) 2 (0.8) 4 (1.7)° 0
* associated with progression of disease
°Reason for treatment withdrawal
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Figure 1 Progression-free survival and Overall Survival in the
study population (n = 45).
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(range 208-1,215) at baseline and post-treatment,
respectively (p value = 0.96); median endostatin serum
level was 102 ng/ml (range 62-281) versus 90 ng/ml
(range 7-184), at baseline and post-treatment, respec-
tively (p value = 0.17). Moreover, the patterns of change
in individual patients were not associated to clinical
response (data not shown).
Discussion
The combination celecoxib-carboplatin is active and
well tolerated in patients with recurrent, heavily treated
OC, with an overall response rate of 28.9% and a med-
ian PFS of 5 months.
These figures compare favourably with previously pub-
lished results (response rate of 6-23%) obtained with
platinum re-challenge in heavily treated recurrent OC
patients [5-7]. We have to bear in mind that in our
study the experimental treatment was administered in
most patients as fourth line chemotherapy, and that half
of cases were characterized by primary or secondary
resistance to platinating agents.
The response rates were found not to be significantly
associated with the grade of platinum-resistance, thus
suggesting a potential influence of celecoxib in favour-
ably modulating the susceptibility to platinating agents.
O n ec o u l da r g u et h a tt h ea c t i v i t yd o c u m e n t e di np l a t i -
num-resistant and relatively sensitive subgroups is com-
parable to the amount of responses reported for
platinum reinduction in these specific populations
[5,7,30-32]. However, so far, it is difficult to directly
compare our results with previously published studies
due to the retrospective design of these series
[5,7,30-32], the type of response assessment (i.e. serolo-
gical versus radiological) [5,31], and the number of pre-
viously administered chemotherapy lines [30-32]: in
order to definitively assess the potential role of celecoxib
in enhancing platinum susceptibility in platinum-sensi-
tive versus platinum-resistant patients a randomised trial
and/or a larger and homogeneous series is required.
Previously reported in vitro studies showed the ability
of selective COX-2 inhibitors to enhance cytotoxicity of
platinating agents and this chemosensitization activity
seems to be apoptosis-mediated and dependent from
the levels of COX-2 expression [19]. Indeed, high intra-
tumoral COX-2 expression has been associated with
chemoresistance in different human cancer, including
OC [10-14]. Moreover, we have recently shown that the
association between COX-2 overexpression and che-
moresistance is documented only for platinum-based
therapy but not for platinum-taxane combination [12].
In this context, it is conceivable that the chemosensitiz-
ing activity of celecoxib could more clearly emerge in
association with a single platinating agent. Indeed, it
c a n n o tb ee x c l u d e dt h a tt h ed i s c o u r a g i n gr e s u l t s
obtained in other studies investigating the chemosensi-
tizing activity of celecoxib, may be also related to the
use of platinum doublets including taxanes or antimeta-
bolites [33-35] while, our study is the only one to our
knowledge, investigating the combination of celecoxib
with a single agent platinating compound.
Our data could appear even more interesting consid-
ering that the celecoxib doses we used (200 mg twice
daily) are considered suboptimal compared to the doses
(400 mg twice daily) previously approved for familial
adenomatous polyposis prevention [18,36], and used in
numerous clinical trials mostly under way [37]. How-
ever, whether lower doses of celecoxib are sufficient or
not to maximally inhibit COX-2 activity is unknown: on
the basis of our results, the dose of 400 mg/day can be
considered clinically as adequate to the main purpose of
chemosensitization. One can argue that we did not find
in the sera of our patients any modulation of key angio-
genesis-related factors, such as the pro-angiogenic
VEGF and the anti-angiogenic endostatin, which have
been previously associated with the antitumoral activity
of celecoxib given at doses of 800 mg/day [16,38]. How-
ever, while higher doses are required to obtain antitu-
moral effects with celecoxib alone in terms of short-
term modulation of molecular markers involved in
tumor growth, apoptosis, immune function or angiogen-
esis [16], these could not be necessary for circumventing
COX-2-mediated chemoresistance mechanisms in com-
binational study with chemotherapy.
As far as treatment safety is concerned, in our study an
acceptable toxicity profile was documented. The chronic
use of selective COX-2 inhibitors has been mainly asso-
ciated with gastroduodenal perforations and intestinal
bleeding [22]: however, in our study no severe gastroin-
testinal event occurred. Moreover, the addition of cele-
coxib did not seem to increase other toxicities classically
associated with the administration of carboplatin, such as
the haematological or neurological ones. As regards the
main concerns recently emerged about the possible,
dose-related, cardiovascular toxicity associated with
chronic exposure to COX-2 inhibitors [23], notwith-
standing enrolled patients were submitted to a median of
3 months of celecoxib-carboplatin, no serious cardiovas-
cular events was reported in our study population: only
one patients experienced a grade 1 venous thrombosis,
recovering after two weeks of therapy. Another patient
developed grade 3 hypertension associated with a grade 2
HSR, thus leading the patient to withdraw the protocol.
In this context, since HSRs are reported in the literature
in about 12-22% of patients submitted to platinum re-
challenge, the rate and grade of severity of HSR observed
in our combination study (i.e. 2.9% of cycles, 13.3% of the
enrolled patients) seems acceptable [25].
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tions, together with the acceptable toxicity profile, sup-
port the safety of the study combination, especially
considering that our patients were heavily chemotherapy
pre-treated, and a half of them were >60 years old.
Moreover, the schedule of carboplatin 5 AUC every 4
weeks, administered in an outpatient setting, and the
oral formulation of celecoxib allowed patients to stay at
home, thus maintaining their family/social relationships,
which are of utmost importance in patients with a short
life-time expectancy. As a confirmation of the good tol-
erability of the study treatment, no QoL deterioration
was observed in the overall population. Besides quality
of life preservation, major goals in the treatment of
heavily treated recurrent OC, include prolongation of
survival: in the overall population, more than half of the
patients survived at least 1 year from the enrolment in
the study. Moreover, most of the patients (about 60%)
experienced a long lasting clinical benefit, in terms of
tumor response or stabilization, showing a median PFS
of 8 months and a median OS of 17 months.
Conclusions
Celecoxib combined with carboplatin in the platinum
re-challenge of heavily-treated recurrent OC patients,
showed promising activity and appeared well tolerated.
This results could promote more tailored clinical trials,
possibly randomised, aimed at drawing more definitive
conclusions about the role of celecoxib in increasing
platinum sensitivity in specific clinical settings. Further
translational studies are necessary to better define the
subgroups of patients taking advantages from the carbo-
platin-celecoxib combination. For instance, the urinary
level of the major prostaglandin E2 metabolite, PGE-M
(11a-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-
dioic acid), has been reported as an effective biomarker
at predicting and selecting patients that may respond to
and benefit from COX-2 inhibition in combination with
traditional therapies [38,39].
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